Our Science

Background

Lakewood-Amedex is a privately held pharmaceutical company that has discovered a novel class of antimicrobial agents called Bisphosphocins with ground-breaking properties that are expected to provide a significant contribution in fighting the Antimicrobial Resistance (AMR) Crisis.

    • At least 700,000 people will die each year due to drug-resistant infections (World Health Organization – WHO)
    • In the US alone more than 2.8 million AMR infections occur each year with more than
      35,000 deaths as a result (Centers for Disease Control and Prevention – CDC)
    • Treatment of the infections caused by six multi-drug resistant germs cost more
      than $4.6 b annually (CDC)
    • Resistance has emerged against most classes of antimicrobial drugs
    • The discovery and launch of new classes of antimicrobial drugs has slowed to a trickle
    • New classes of AMR drugs are urgently needed